Global R&D management

Huntsman Launches Technology Portal to Foster Innovation & Manufacturing-Driven Collaborations

Retrieved on: 
Monday, September 25, 2023
Huntsman Corporation, Global R&D management, Advanced Materials, Innovation, Marketing, Simpson Performance Products, NYSE, Sales, Huntsman

The cross-divisional initiative aims to facilitate and foster external collaborations, connecting minds and expertise from diverse sectors with Huntsman to unlock potential business opportunities.

Key Points: 
  • The cross-divisional initiative aims to facilitate and foster external collaborations, connecting minds and expertise from diverse sectors with Huntsman to unlock potential business opportunities.
  • "Collaboration is a key element of our innovation process at Huntsman," said Dr. David Hatrick, Vice President of Strategic Marketing and Innovation for Huntsman's Advanced Materials division.
  • The Huntsman Technology Portal will make it easier for external parties to propose and request new solutions, technologies and capabilities that could be jointly developed to create value for them and Huntsman."
  • Reflecting the company's commitment to deep collaborations, Huntsman Technology Portal offers two distinct cooperation routes for:
    Innovation-driven Solutions: streamlined interface for innovators and entrepreneurs to share innovation challenges, problems to solve, and collaboration opportunities with Huntsman.

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

Retrieved on: 
Wednesday, September 6, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Teva Pharmaceuticals, HD, Abstract (summary), LAI, Risk, Different Stages, TEVA, Global R&D management, Olanzapine, Teva, De novo, TD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lais, Doctor of Philosophy, Medication, Depression, Risperidone, Poster, Migraine, MD, Treatment, TASE, Post hoc analysis, Chorea, Reactions on surfaces, FDA, Mental health, NYSE, Tardive dyskinesia, Food, Pharmaceutical industry, Patient, Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 16 data presentations across its neuroscience portfolio happening at Psych Congress on September 6-10 in Nashville, TN.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 16 data presentations across its neuroscience portfolio happening at Psych Congress on September 6-10 in Nashville, TN.
  • Abstracts include data for AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY.
  • Once-daily AUSTEDO XR, a new formulation of twice-daily AUSTEDO was approved by the U.S. Food and Drug administration (FDA) in February 2023 for adults with TD and chorea associated with Huntington’s disease (HD), and UZEDY, a long-acting formulation of risperidone for subcutaneous use, was approved by the FDA in April 2023 for adults with schizophrenia.1,2 TV-44749 is an investigational formulation of olanzapine currently being studied in adults with schizophrenia.3
    “Because of the immense impact that mental health and neurological conditions like schizophrenia, TD and HD pose for patients, we are constantly striving to advance research that can enhance available treatment options,” said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva.
  • “Following this year’s FDA approval of once-daily AUSTEDO XR and UZEDY and the excitement they have received from the medical community, we are thrilled to continue to share research showcasing their potential for patients living with these debilitating conditions.”
    In addition to these data presentations, Teva will also be hosting a symposium to discuss results of the DECIDE study, highlighting perspectives from U.S. psychiatric clinicians on selecting and initiating LAI antipsychotics as well as the real-world barriers that cause LAIs to remain underutilized in clinical practice.

WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS

Retrieved on: 
Thursday, July 20, 2023
TSX, Partnership, Food, Global R&D management, WLLW, Willow Garage, Fine chemical, Management

KALAMAZOO, Mich. and SUNNYVALE, Calif., July 20, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, announce they are advancing their functional ingredient development program for a large volume savory foods opportunity.

Key Points: 
  • KALAMAZOO, Mich. and SUNNYVALE, Calif., July 20, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, announce they are advancing their functional ingredient development program for a large volume savory foods opportunity.
  • After a successful phase one feasibility program that applied Willow's BioOxi™ platform exceeded expectations, Kalsec has agreed to continue full development toward commercialization that includes additional R&D and scale-up work.
  • Willow expects to continue generating revenue from research fees and milestones, aligning with its strategic focus on near-term revenue generation on programs bringing commercial revenue in reasonable timeframes, with anticipated ongoing negotiation of commercial terms as the program advances.
  • "We appreciate the trust Kalsec has in Willow to help with their innovation pathway and are delighted to partner with them on this next step in our engagement on ingredient development," said Dr. Chris Savile, Willow's President & CEO.

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Psych, Teva Pharmaceuticals, Interim, Risk, VMAT2, TEVA, Global R&D management, START, Teva, Use, TD, De novo, State University of New York Upstate Medical University, Safety, Efficacy, Clinical Global Impression, Doctor of Philosophy, Patient, Medication, PGIC, Tablet, Congress, DE, User experience, MD, Poster, Randomness, TASE, Olanzapine, Annual general meeting, Chorea, Treatment, AM, Effectiveness, Reactions on surfaces, XR, FDA, Mental health, Tardive dyskinesia, NYSE, SHINE, Pharmaceutical industry, Nursing, Tolerability, Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.
  • Two presentations feature real-world data for AUSTEDO (deutetrabenazine) tablets for adults living with TD.
  • Data presented will include interim findings from the START trial, a Phase 4 study investigating real-world utilization of AUSTEDO with a 4-week patient titration kit along with treatment success as measured at the end of treatment.
  • Teva will also present findings from studies evaluating potential drug-drug interactions with VMAT2 inhibitors, as well as patient and healthcare provider perspectives on the impact of TD.

KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT

Retrieved on: 
Tuesday, May 23, 2023
Partnership, Food, Global R&D management, Master service agreement, Science, Nature, MSA, Willow Garage, TSX, WLLW, Willow, Fine chemical, Management

"We look forward to further evidencing our technological capabilities through what we believe will be a similarly successful outcome for this next program."

Key Points: 
  • "We look forward to further evidencing our technological capabilities through what we believe will be a similarly successful outcome for this next program."
  • Kalsec's projects focus on yeast, which, among other applications, is an ideal host for production of numerous ingredients for the food and beverage sector.
  • By working closely with their customers, the development team at Kalsec has identified multiple potential opportunities for collaboration and innovation in this space.
  • "We are excited to expand our partnership with Willow and leverage each party's significant domain expertise toward what we believe will be successful commercial-scale production in 2024."

Ahlstrom ECO™, a renewable lignin-impregnated filter media, wins the American Filtration Society's New Product of the Year award

Retrieved on: 
Wednesday, May 10, 2023
Ahlstrom-Munksjö, Consumer Packaging and Labeling Act, Lignin, Engineers for a Sustainable World, AFS, Global R&D management, EUR, Building material, Filtration, R, Transport, Food, New product development, Fine chemical, Renewable energy, Health care

The Product of the Year award is given to a company introducing the most significant new product in the previous year.

Key Points: 
  • The Product of the Year award is given to a company introducing the most significant new product in the previous year.
  • "Being acknowledged by the AFS and receiving this award for Ahlstrom ECO™ is a great achievement.
  • Ahlstrom ECO™ is a renewable and sustainable filter media which utilizes lignin-based impregnation, thereby limiting the use of fossil-based resin.
  • Ahlstrom ECO™ supports the increased sustainability demands of the global transportation market and offers a new choice for filter manufacturers.

Teva Announces Appointment of New Global R&D and Chief Medical Officer

Retrieved on: 
Friday, July 1, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Translation, Immunology, Department, Translational medicine, Annual report, Board of directors, University School, Patient, CEO, Novartis, Merck & Co., Global R&D management, Senior, Biomarker, COVID-19, Failure, Internal medicine, Industry, TASE, Yale school, Hotel manager, Employment, Yale School of Medicine, TEVA, Compliance, Yale New Haven Hospital, Infection, Investment, Private Securities Litigation Reform Act, NYSE, Doctor of Philosophy, Bristol, Head, Bristol Myers Squibb, Vertex Pharmaceuticals, Drug development, Leadership, Hepatology, Multimedia, Forward-looking statement, Director, Pharmaceutical industry, Management, Fine chemical, Virology, Teva, Autoimmunity, MD

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer.
  • Dr. Hughes stated, "I am thrilled to join Teva's executive management team and lead its unique, integrated Global R&D organization.
  • Dr. Hughes has held senior positions at Vertex Pharmaceuticals, a U.S. based global biotechnology company and at Novartis.
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century.

Pacaso Debuts First-Ever Global Advertising Campaign, "Own It"

Retrieved on: 
Monday, March 14, 2022
Pernod Ricard, Brighthouse Financial, SAN, Life, Partnership, Walmart, Hulu, Advertising, Marvel, Own It, Culture, IPG, Multimedia, LinkedIn, Global R&D management, NYSE, The Interpublic Group of Companies, BBH, Netflix, Radical, Ownership, Growth, Adweek, Intelligence, Lionsgate, CEO, Samsung, Google, Creativity, AOR, Tourism, Public relations, Glassdoor, Mediahub

SAN FRANCISCO, March 14, 2022 /PRNewswire/ -- Pacaso, the leading technology-enabled real estate marketplace that helps people buy and co-own a luxury second home, today debuts "Own It," the company's inaugural national advertising campaign, in collaboration with its two newly appointed agency partners: award-winning creative agency BBH USA, and decorated global media agency Mediahub.

Key Points: 
  • The global media campaign will launch on March 14, 2022, in strategic markets in the U.S., UK, Germany, and Sweden.
  • Pacaso is a category-creating brand, giving people the opportunity to own a luxury second home for the cost.
  • "Our inaugural campaign speaks to the Pacaso mission of making second home ownership possible and enjoyable for more people.
  • Pacaso generated nearly $300 million in revenue in 2021, the company's first full year, and sold approximately 400 Pacaso units, among many other noteworthy brand milestones.

BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China

Retrieved on: 
Thursday, August 26, 2021
Company, National Medical Products Administration, Priority review, PD-1, Therapy, Cancer, Global R&D management, U.S. Securities and Exchange Commission, EGFR, Large-cell lung carcinoma, Shanghai Stock Exchange, Medication, GLOBE, Knowledge, COGS, Research, PDUFA, CIN, Director, Food, Form 20-F, Docetaxel, G-CSF, Breakthrough therapy, NDA, Marketing, NEW, Forward-looking statement, NMPA, Board, NASDAQ, Safety, APC, B cell, HSPC, Patient, Partnership, Neutropenia, Neoplasm, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Fine chemical, Telecommunication, Pharmaceutical industry

Wanchunbulin and Hengrui will co-develop additional indications for plinabulin in the Territory; Hengrui funds 50% of future clinical development costs for new cancer indications in the Territory.

Key Points: 
  • Wanchunbulin and Hengrui will co-develop additional indications for plinabulin in the Territory; Hengrui funds 50% of future clinical development costs for new cancer indications in the Territory.
  • NEW YORK and SHANGHAI, China, Aug. 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the Company or BeyondSpring) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (or Hengrui) today announced an exclusive commercialization and co-development agreement in Greater China (the Territory) for BeyondSpring's investigational drug candidate plinabulin, a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA).
  • BeyondSpring will still retain 100% of the global plinabulin rights outside of Greater China.
  • Under the terms of the agreement, Wanchunbulin will grant Hengrui exclusive rights to commercialize and co-develop plinabulin in the Greater China markets, including mainland China, Hong Kong, Macau and Taiwan.